260 results on '"Seghatchian, Jerard"'
Search Results
2. Towards personalized and rational use of immunoglobulins amid expanding indications and shortages.
3. Editorial comments: Two clinical viewpoints from Oslo.
4. Editorial comments: Looking for some innovative diagnostic or developmental research studies that might influence our laboratory and clinical decision-making.
5. Spotlights on the trends in performance assessment of qualitative in vitro diagnostic medical devices in transfusion medicine.
6. Editorial commentary.
7. Editorial commentary - A snapshot on the role of newer technologies identifying variability in donor red cell storage stability and its implications on recipients' clinical outcome.
8. What's happening CAR T cell immunotherapy.
9. An invite for evidence-based insights and expert viewpoints on blood donor recruitment and retention.
10. What's happening editorial commentary: Immunological impacts CD71+RBC subpopoulation present in stored blood and validation of a new irradiation system for off-line EPC.
11. T-cell lymphocytopenia: An omnipresent predictor of morbidity and mortality in consequence of SARS-CoV disease and influenza A infections.
12. Spotlight on the impact of transfusion support, the detrimental influence of blood donation microbiomes on hematological immune-related toxicities, and the sustained efficacy and survival outcomes of immune checkpoint inhibitors' treated cancer patients.
13. Cryopreservation of apheresis platelets treated with riboflavin and UV light.
14. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now!
15. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes.
16. Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events.
17. Spotlight on the impacts of transfusion on patients with Autoimmune Rheumatic Diseases.
18. Blood transfusion in autoimmune rheumatic diseases.
19. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron.
20. Do highly transmissible omicron subtypes BA.4/BA.5 have any impact on the HLA class I /II antibodies of apheresis donors, and could mucosal omicron-specific vaccines prevent transmissibility and provide more durable protection?
21. Editorial: Time to explore the missing links: the cross-talk between COVID infection and cancer cells; lingering questions on the longitudinal efficacy of the front line immunotherapies against unpredictable "Omicron ghosts" and insights from CAR-T cell therapy pointing toward better clinical outcomes.
22. SARS-CoV-2 and cancer: the intriguing and informative cross-talk.
23. Editorial: Time to explore the missing links: from activated platelets and platelet extracellular vesicles in SARS-CoV-2 infection, through heterogeneity in the host physiological, immuno-inflammatory and haemostatic responses to mRNA-based vaccine or infection induced polyclonal neutralizing antibodies and passive immunity.
24. Platelet and extracellular vesicles in COVID-19 infection and its vaccines.
25. Editorial: An all-round appraisal of the latest viewpoints on "Acute Thrombotic Coagulability" and an update on the "inflammation-conditioned" profiles of platelets in sepsis patients.
26. An appraisal of the latest achievements on platelet lysate designed for clinical opportunities in regenerative medicine and cellular therapy.
27. Spotlights on "Process capability index trends": A new development in the manufacturing of blood components and related industries.
28. Spotlight on the latest trends on CoV-2 Alpha and Delta variants in the UK; Targeting blood donor population for assessing the effect of the mRNA vaccines on the seroprevalence of CoV-2 Delta variant antibodies and reflections on the management of alloimmunisation in transfused patients with constitutional anaemias in Norway.
29. Back to basics on assessment of extracellular vesicle activity states, using modern captured based assays, combined with innovative IFC and proteomics, that might become tomorrow's realities.
30. Polycythaemia vera: molecular genetics, diagnostics and therapeutics.
31. Exploratory spotlights on the proteome of extracellular vesicles in red blood cell units prepared by the same donors revealed that leukoreduction may matter for the quality and safety of transfusion therapy: Back to basics for research topics that might begin tomorrow's realities.
32. Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders.
33. Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount.
34. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.
35. On the Quest for In Vitro Platelet Production by Re-Tailoring the Concepts of Megakaryocyte Differentiation.
36. An introductory commentary on the use of artificial intelligence, machine learning and TQM, as novel computational tools in big data patterns or procedural analysis, in transfusion medicine.
37. An Overview of Current Position on Cell Therapy in Transfusion Science and Medicine: From Fictional Promises to Factual and Perspectives from Red Cell Substitution to Stem Cell Therapy.
38. Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!
39. Assessment of extracellular vesicles using IFC for application in transfusion medicine.
40. Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity.
41. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research.
42. Updates on Stem Cell Therapy in Transfusion Medicine, New Approaches to RBC Substitution Therapy, the Use of IFC for the Assessment of Extracellular- Derived Vesicles/Exosomes.
43. Cell culture - Fact and fiction.
44. In vitro platelet production for transfusion purposes: Where are we now?
45. Spotlight on the current perspectives on applications of human blood cell culture and organoids: Introductory remarks.
46. In vitro mass production of reproducible human cells destined for substitution therapy: Challenges for development of functional materials for what we need most in transfusion!
47. The secrets of human stem cell-derived transfusable RBC for targeted large-scale production and clinical applications: A fresh look into what we need most and lessons to be learned.
48. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients.
49. Opportunities for standardization of cold stored, low-titre group O WB products.
50. Shedding light on the quality profiles of stem cells, whole blood and the supply of cryopreserved blood-derived bioproducts.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.